What is Zacks Research’s Forecast for CRL FY2027 Earnings?

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities researchers at Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Charles River Laboratories International in a report issued on Wednesday, March 12th. Zacks Research analyst R. Department expects that the medical research company will earn $11.39 per share for the year. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same period last year, the business posted $2.46 earnings per share. The firm’s revenue for the quarter was down 1.1% on a year-over-year basis.

A number of other research firms have also recently issued reports on CRL. The Goldman Sachs Group cut their target price on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Barclays decreased their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 18th. JPMorgan Chase & Co. reduced their price target on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. Finally, Bank of America reduced their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $198.36.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $171.27 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The stock has a market capitalization of $8.76 billion, a PE ratio of 1,141.78, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International has a 12-month low of $150.79 and a 12-month high of $274.77. The business’s fifty day moving average price is $167.74 and its 200 day moving average price is $184.72.

Institutional Investors Weigh In On Charles River Laboratories International

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in shares of Charles River Laboratories International in the third quarter worth about $601,000. JPMorgan Chase & Co. boosted its stake in Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after purchasing an additional 85,759 shares during the period. State Street Corp boosted its stake in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after purchasing an additional 41,421 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its holdings in Charles River Laboratories International by 3.4% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company’s stock valued at $22,060,000 after acquiring an additional 3,714 shares in the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of Charles River Laboratories International by 7.6% during the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock worth $9,064,000 after buying an additional 3,268 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Insider Activity

In other Charles River Laboratories International news, CEO James C. Foster acquired 6,075 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The shares were bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).